Oculis (NASDAQ:OCS) Shares Gap Up – Should You Buy?

Oculis Holding AG (NASDAQ:OCS)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $16.50, but opened at $16.98. Oculis shares last traded at $16.98, with a volume of 700 shares traded.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of Oculis in a research note on Monday, November 11th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $29.20.

Oculis Stock Up 3.0 %

The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.02 and a current ratio of 4.02. The company has a market capitalization of $692.15 million, a price-to-earnings ratio of -8.85 and a beta of -0.34. The business has a 50-day simple moving average of $15.72 and a two-hundred day simple moving average of $13.18.

About Oculis

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.